KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Inventory (2016 - 2026)

Pacific Biosciences Of California has reported Inventory over the past 16 years, most recently at $49.3 million for Q4 2025.

  • For Q4 2025, Inventory fell 16.12% year-over-year to $49.3 million; the TTM value through Dec 2025 reached $49.3 million, down 16.12%, while the annual FY2025 figure was $49.3 million, 16.12% down from the prior year.
  • Inventory for Q4 2025 was $49.3 million at Pacific Biosciences Of California, down from $53.2 million in the prior quarter.
  • Over five years, Inventory peaked at $68.6 million in Q2 2024 and troughed at $16.3 million in Q1 2021.
  • A 5-year average of $49.7 million and a median of $53.8 million in 2025 define the central range for Inventory.
  • Biggest five-year swings in Inventory: soared 109.13% in 2023 and later decreased 21.51% in 2025.
  • Year by year, Inventory stood at $24.6 million in 2021, then surged by 104.81% to $50.4 million in 2022, then increased by 12.49% to $56.7 million in 2023, then increased by 3.67% to $58.8 million in 2024, then dropped by 16.12% to $49.3 million in 2025.
  • Business Quant data shows Inventory for PACB at $49.3 million in Q4 2025, $53.2 million in Q3 2025, and $53.8 million in Q2 2025.